BioLineRX
BLRX
30 hedge funds and large institutions have $16.3M invested in BioLineRX in 2019 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 7 reducing their positions, and 6 closing their positions.
212% more capital inflows, than outflows
Capital inflows: $1.47M | Capital outflows: $471K
0.26% more ownership
Funds ownership: 5.02% → 5.29% (+0.26%)
9% less funds holding
Funds holding: 33 → 30 (-3)
29% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 7
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Senvest Management
New York
|
+$1.32M |
| 2 |
Delek Group
Herzliya,
Israel
|
+$105K |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
+$18.1K |
| 4 |
Cutter & Co Brokerage
Ballwin,
Missouri
|
+$11.1K |
| 5 |
Virtu Financial
New York
|
+$6.12K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fosun International
Hong Kong,
China
|
-$304K |
| 2 |
Menta Capital
San Francisco,
California
|
-$33K |
| 3 |
Renaissance Technologies
New York
|
-$27K |
| 4 |
Two Sigma Securities
New York
|
-$25K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$22.7K |
BLRX Hedge Fund Activity: Q1 2019 in Review
30 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q1 2019, worth a combined $16.3M — up 3.4% from $15.7M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of BLRX and 4 opened new positions — a net loss of 2 holders — while 7 trimmed existing stakes and 5 added.
The largest buyer was Senvest Management, adding an estimated $1.32M. The largest seller was Fosun International, cutting an estimated $304K.
- 30 institutional investors held BioLineRX (BLRX) as of Q1 2019, down from 33 in Q4 2018.
- Funds reported $16.3M of BioLineRX stock for Q1 2019, up 3.4% quarter-over-quarter.
- 4 funds opened new BioLineRX positions in Q1 2019 and 6 closed out, a net change of -2 holders.
- The largest BioLineRX buyer in Q1 2019 was Senvest Management, an estimated $1.32M added.
- The largest BioLineRX seller in Q1 2019 was Fosun International, an estimated $304K sold.
Based on aggregated 13F filings for Q1 2019.